Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Pharmaceuticals – December 31, 2022
Source: OpenAlex
Summary
Psilocybin shows significant promise for alleviating depressive symptoms, suggesting a powerful new direction in Psychiatry and Medicine. However, establishing its full Credibility requires addressing current limitations in Psychedelics and Drug Studies. Early findings often stem from small sample sizes and face challenges like blinding and limited follow-up. Standardized protocols are crucial to understand this potent compound, an alkaloid from Chemical synthesis. Future research, leveraging robust Data science, must clarify Psilocybin's real potential as a therapeutic molecule for Depression and other psychological conditions, ensuring diverse academic research themes contribute to its safe and effective application.
Abstract
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up, highly screened treatment populations) and some health/political issues, including practitioners’ experience, lack of standardized protocols, psychedelics’ legal status, ethical concerns, and potential psychological/psychopathological/medical untoward effects. The focus here is on a range of clinical and methodological issues, also aiming at outlining some possible suggestions. We are confident that newer evidence, more precise protocols, and eventual reclassification policies may allow a better understanding of the real potential of psilocybin as a transdiagnostic therapeutic molecule.